SEC Filing Summary: BioZone Pharmaceuticals, Inc.
Business Context and Reporting Period
This Form 8-K was filed by BioZone Pharmaceuticals, Inc. (not Cocrystal Pharma, Inc.) on September 26, 2012. The report addresses a material accounting error discovered by the Chief Financial Officer regarding previously issued financial statements for the quarters ended March 31, 2012, and June 30, 2012.
Key Financial Metrics
The filing does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on the identification of an accounting error rather than reporting operational financial results.
Material Changes and Restatement
- Non-Reliance Notice: The Company announced that its Quarterly Reports (Form 10-Q) for the periods ended March 31, 2012, and June 30, 2012, should no longer be relied upon.
- Source of Error: The misstatement pertains to the accounting treatment for the issuance of certain convertible promissory notes.
- Corrective Action: The Company plans to file amendments to the affected Quarterly Reports as soon as practicable to restate the financial statements with necessary accounting corrections.
Management Commentary and Risks
The Chief Financial Officer, Elliot Maza, concluded the error required restatement. The matter was discussed with Paritz and Company, P.A., the Company's independent registered public accounting firm. The primary risk identified is the potential impact of the restatement on the Company's reported financial condition and results of operations for the first half of 2012.
Investor Verification Checklist
- Verify the specific magnitude of the restatement once the amended Form 10-Q filings are released.
- Confirm the impact of the convertible promissory note accounting error on the Company's debt obligations and equity structure.
- Review the Company's internal controls over financial reporting to understand how the error occurred.
- Monitor for any additional disclosures regarding the relationship with the independent auditor, Paritz and Company, P.A.